Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report)'s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $17.39. Crescent Biopharma shares last traded at $15.55, with a volume of 106,463 shares trading hands.
Analyst Ratings Changes
Several equities research analysts have issued reports on CBIO shares. TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research note on Friday, June 20th. Lifesci Capital raised Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price on the stock in a research report on Wednesday, June 18th. Finally, Stifel Nicolaus initiated coverage on Crescent Biopharma in a report on Wednesday, June 25th. They set a "buy" rating and a $28.00 target price on the stock.
Check Out Our Latest Research Report on CBIO
Crescent Biopharma Stock Performance
The company has a market cap of $304.00 million, a price-to-earnings ratio of -0.34 and a beta of 1.52.
Crescent Biopharma Company Profile
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
